Technology
Health
Medical

LivaNova

$94.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.66 (-0.69%) Today
-$0.66 (-0.69%) Today

Why Robinhood?

You can buy or sell LivaNova and other stocks, options, ETFs, and crypto commission-free!

About

LivaNova PLC Ordinary Shares, also called LivaNova, is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the Cardiac Surgery and Neuromodulation, and Other Corporate segments. Read More The Cardiac Surgery and Neuromodulation segment corresponds to the primary therapeutic areas. The Other Corporate segment includes corporate business development and New Ventures. The company was founded on October 19, 2015 and is headquartered in London, the United Kingdom.

Employees
4,500
Headquarters
London, Greater London
Founded
2015
Market Cap
4.64B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
481.62K
High Today
$95.90
Low Today
$94.50
Open Price
$95.51
Volume
13.75K
52 Week High
$131.54
52 Week Low
$79.96

Collections

Technology
Health
Medical
Healthcare
2015 IPO
UK
Europe

News

Markets InsiderMar 18

LivaNova Announces Trui Hebbelinck as Chief Human Resources Officer

Livanova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Trui Hebbelinck has been appointed Chief Human Resources Officer for the Company.

2
Yahoo FinanceMar 15

LivaNova to Present Autonomic Regulation Therapy Findings for Chronic Heart Failure Patients at the American College of Cardiology 68th Annual Scientific Session

LONDON--(BUSINESS WIRE)-- LivaNova PLC (LIVN), a market-leading medical technology company, today announced it will present three abstracts supporting the use of implantable neuromodulation technology to treat chronic heart failure during the American College of Cardiology 68th Annual Scientific Session (ACC 2019) from March 16-18 in New Orleans, USA. The LivaNova VITARIA® System delivers Autonomic Regulation Therapy (ART) using Vagus Nerve Stimulation (VNS) to treat patients with chronic, symptomatic hea...

3
TradingNewsNowMar 13

Recent Valuation: LivaNova (NASDAQ: LIVN)

LivaNova trades as part of the healthcare sector and medical devices industry. The company CEO is Damien McDonald. LivaNova is a medical technology company formed by the merger of Sorin S.p.A, engaged in the treatment of cardiovascular diseases, and Cyberonics, a medical device company with core expertise in neuromodulation. Previous Intraday Trading Performance: The LIVN stock showed a previous change of -0.02% with an open at 94.77 and a close of 94.85. It reached an intraday high of 95.05 and a low of ...

4

Earnings

$0.65
$0.81
$0.96
$1.12
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.